Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This study is currently recruiting patients.
Sponsored by: | National Cancer Institute (NCI) |
---|---|
Information provided by: | Warren G Magnuson Clinical Center (CC) |
Purpose
This experiment will test the safety and effectiveness of a treatment for metastatic melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's immune system has been weakened with immune-suppressing drugs. Some patients will also receive interleukin-2, a drug that may enhance the activity of the re-infused lymphocytes.
Patients with metastatic melanoma (melanoma whose tumor has spread) who have been treated unsuccessfully with gp100 vaccination may participate in this study. They will undergo apheresis or a tumor biopsy, or both, to collect lymphocytes. In apheresis, whole blood is drawn through a needle in the arm. A machine separates the blood components and removes the white cells. The rest of the blood is returned through a needle in the other arm. A biopsy is a surgical procedure to remove a small piece of tumor tissue. We will find the best cells to fight the melanoma from cells obtained from the pheresis or biopsy. We will take these and grow them in larger numbers in the laboratory. These are called "cloned cells" because we grow a lot of cells that are exactly like the best melanoma fighting cells we started with.
Several weeks before we weaken the immune system and give the "cloned cells", additional lymphocytes are collected after patients receive injections of G-CSF every day for five days. This drug stimulates white cell production, permitting as many cells as possible to be obtained during collection. These white cells will be frozen in the laboratory and will only be given back to the patient if their immune system does not completely recover from the chemotherapy drugs used to suppress the immune system.
Seven days before the "cloned cells" are re-infused, the patient is admitted to the hospital and a catheter (small tube) is placed in a large vein in the chest or neck. Two drugs, cyclophosphamide and fludarabine, are given through the tube. These drugs suppress the immune system so that it will not interfere with the work of the reinfused lymphocytes. The lymphocytes are then given through the catheter over a 30-minute period. After the infusion, patients who receive IL-2 will be given the drug over a 15-minute period every 8 hours for up to 5 days. Fourteen to 21 days after this, the patient will be given a second infusion of "cloned cells".
Blood and tissue samples will be taken before and during the study to evaluate the size of the tumor and response to treatment. If, 3 to 5 weeks after therapy is completed, scans and x-rays of the patient's tumor show that is has stabilized or shrunk, the cell treatment, except for chemotherapy, may be repeated two more times.
Condition | Treatment or Intervention | Phase |
---|---|---|
Melanoma Neoplasm Metastasis |
Drug: gp100:209-217 (210M) Drug: Montanide ISA-51 Drug: IL-2 Drug: Retroviral Vector PG13/LNC8 Drug: OKT3 Drug: MART-1:26-35(27L) |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Melanoma
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy
Official Title: Treatment of Patients with Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Non-Myeloablative but Lymphocyte Depleting Regimen
Expected Total Enrollment: 220
Study start: August 26, 1999
Patients with metastatic melanoma who are HIV and Hepatitis B negative and who have previously progressed after receiving standard therapy will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine and then will be treated by the adoptive transfer of lymphocytes reactive with shared antigens on their tumors. This study will evaluate the toxicity, immunologic effects and potential therapeutic role of this treatment.
Eligibility
Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Location and Contact Information
More Information
Publications
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |